- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02273271
Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative Chemo (EVIDENCE)
Evaluation of 3'-Deoxy-3'-[18F]Fluorothymidine -PET and Diffusion Weighted Imaging -MRI in Patients With Early Stage Non-small Cell Lung Cancer Treated With a Platinum-based Doublet as Preoperative Chemotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, multicenter, single-arm imaging trial. Patients with NSCLC will undergo 18F-FLT-PET/CT and DWI-MRI scans on three separate occasions: at baseline, at 14 days (maximum +/- 1 days deviation is acceptable) after first administration of chemotherapy and finally after up to 4 cycles of chemotherapy, and then followed by surgery. The quantification of 18F-FLT SUV and ADC will be measured to assess tumor characteristics and response to therapy.
Patients will be first registered into the EORTC system after signing the informed consent form. The site will have to complete all the study related procedures within 6 weeks prior to treatment and all eligibility criteria should be met before the patient can be enrolled into the study.
Both 18F-FLT-PET/CT and DWI-MRI will be assessed independently in this trial. Therefore the overall type I error of 0.1 will be split by two in order to test independently each imaging biomarker with a one-sided type I error of 0.05. In order to demonstrate with 95% confidence interval (one sided) that the correlation between the imaging biomarker change and the pathological response is > 0.5 (H0: rho ≤ 0.5) with 90% power if the true correlation is 0.8 (H1: rho > 0.5), 31 lesions are needed. As, in this population, patients only have the primary tumor, 31 eligible and evaluable patients will be needed for each primary endpoint.
If all included patients have both 18F-FLT-PET/CT and DWI-MRI then 31 eligible and evaluable patients will be enough. If some patients have only one type of scans (18F-FLT-PET/CT or DWI-MRI), the sample size would need to be adapted to have 31 patients with each type of scans.
In addition, the total number of patients to be registered may be increased to 40 patients for each primary endpoint to take into account some screening failure.
For the primary analysis of correlation between relative change in imaging biomarkers (18F-FLT-SUV or ADC) and pathological quantification, the correlation coefficient will be reported using a one-sided 95% confidence interval, and tested as a one-sided comparison to the null hypothesis (H0: ρ ≤ 0.5). All secondary objectives to correlate preoperative imaging biomarkers and IHC biological markers or tumor volume will use the same analysis as cited above with 99% confidence intervals. All measures will be analyzed in a random effect ANOVA model allowing for within center-variability.
Quality assurance is planned for the control of data consistency, on-site monitoring, audits, and quality assurance in pathological response assessment and in imaging.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Oussama Karroum
- Phone Number: 003227741523
- Email: oussama.karroum@eortc.be
Study Contact Backup
- Name: Leslie Herman
- Phone Number: 003227741511
- Email: leslie.herman@eortc.be
Study Locations
-
-
-
Milano, Italy, 20089
- Recruiting
- Istituto Clinico Humanitas
-
Contact:
- Arturo Chiti, Medical doctor
- Phone Number: +39 02 8224 6621
- Email: arturo.chiti@hunimed.eu
-
Principal Investigator:
- Arturo Chiti, MD
-
-
-
-
-
Sutton, United Kingdom
- Recruiting
- Royal Marsden Hospital - Sutton, Surrey
-
Contact:
- Nandita Desouza, MD
- Phone Number: +44 2086613289
- Email: nandita.desouza@icr.ac.uk
-
Principal Investigator:
- Nandita Desouza, MD
-
Sub-Investigator:
- Sanjay Popat, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years
- WHO performance status 0-1 (Appendix C)
- Histologically or cytological confirmed clinical stage II-IIIA non-small cell lung carcinoma (NSCLC), according to 7th TNM classification (Appendix D) (NOTE: patients with resectable N2 disease are also eligible)
- Baseline standard imaging assessment & staging should be performed within 6 weeks prior to planned treatment start.
Patients must be candidate for curative intent surgery, and must be expected to complete the treatment.
♦♦ Adequate hematology and biochemical investigations, (should be done maximum 6 weeks before treatment starts)
- Normal bone marrow function based on routine blood samples, i.e. neutrophils ≥ 1.5 x 109/L, platelets ≥ 75 x 109/L, hemoglobin ≥ 10.0 g/dL
- Normal kidney function creatinine clearance ≥ 60 mL/min,
- Normal liver function assessed by routine laboratory examinations, i.e. bilirubin < 1.5 x upper limit of normal (ULN), ALT< 3 x ULN
- Patients must not have any contraindication for 18F-FLT-PET/CT or MRI procedures.
- Patient primary lung tumor larger than 20 mm in diameter (measured by diagnostic CT or MRI).
- Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test before trial registration.
- Patients of childbearing / reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 6 months after the last study procedure. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
- Female subjects who are breast feeding should discontinue nursing before trial registration.
- Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.
Exclusion Criteria:
- Prior or current anticancer treatment for NSCLC, pre-operative therapy will include only chemotherapeutic drugs (pemetrexed is contraindicated), no other biological, targeted or radiotherapy is allowed
- Treatment with any investigational drug substance within 4 weeks prior to registration.
- Other malignancies in the 3 years prior to study entry with the exception of surgically cured carcinoma in situ of the cervix, in situ breast cancer, incidental finding of stage T1a or T1b prostate cancer, and basal/squamous cell carcinoma of the skin
- Evidence of any medical condition which would impair the ability of the patient to participate in the trial or might preclude therapy with chemotherapeutic drugs according to routine medical practice (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease, known dihydropyrimidine dehydrogenase deficiency, active infection, uncontrolled diabetes mellitus; uncontrolled arterial hypertension, history of unstable myocardial infarction)
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Imaging arm
18F-FLT-PET/CT and DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 4 cycles of chemotherapy
|
Patients with NSCLC will undergo 18F-FLT-PET/CT and DWI-MRI scans on three separate occasions.
Dedicated in-house developed software will be used to quantify 18F-FLT SUV and ADC to assess tumor characteristics and response to therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Apparent Diffusion Coefficient (ADC) change
Time Frame: day 14 relative to baseline
|
Percentage of Apparent Diffusion Coefficient (ADC) change at day 14 relative to baseline
|
day 14 relative to baseline
|
Percentage of FLT uptake change
Time Frame: day 14 relative to baseline
|
Percentage of FLT uptake change at day 14 relative to baseline
|
day 14 relative to baseline
|
Pathological quantification (% viable residual tumor cells)
Time Frame: in average at week 16 from baseline
|
participants will receive chemotherapy for up to 12 weeks (4 cycles) and followed by surgery (with an expected surgical preparation of 2-4 weeks)
|
in average at week 16 from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pre-operative (post-treatment) ADC measurement
Time Frame: in average at week 15 from baseline
|
participants will receive chemotherapy for up to 12 weeks (4 cycles) and performed the DWI-MRI scan within one week prior to the surgery
|
in average at week 15 from baseline
|
Pre-operative (post-treatment) FLT uptake measurement
Time Frame: in average at week 15 from baseline
|
participants will receive chemotherapy for up to 12 weeks (4 cycles) and performed the FLT-PET scan within one week prior to the surgery
|
in average at week 15 from baseline
|
Tumor volume (baseline, day 14 and post-treatment)
Time Frame: baseline, day 14 and post-treatment
|
baseline, day 14 and post-treatment
|
|
Immunohistochemistry (IHC) cell proliferation marker Ki-67
Time Frame: 1y
|
Immunohistochemistry (IHC) cell proliferation marker Ki-67-index in diagnostic biopsy samples (if available) and surgical specimens.
|
1y
|
Metabolic change from FDG-PET (if available)
Time Frame: in average at week 9 from baseline
|
standard imaging per routine practice
|
in average at week 9 from baseline
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nandita deSouza, Royal Marsden Hospital - Sutton, Surrey
- Study Chair: Sanjay Popat, Royal Marsden Hospital - Chelsea, London
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EORTC-1217
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Carcinoma
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on 18F-FLT-PET/CT and DWI-MRI
-
National Cancer Institute (NCI)CompletedNeurofibromatosis | MPNSTUnited States
-
University of Texas Southwestern Medical CenterWithdrawnSolid TumorUnited States
-
Memorial Sloan Kettering Cancer CenterWithdrawnHistologically-confirmed MalignanciesUnited States
-
Masonic Cancer Center, University of MinnesotaTerminatedHematologic MalignancyUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
National Cancer Centre, SingaporeRecruitingCervix Cancer | Image, BodySingapore
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedProstate CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterWithdrawnBrain Metastasis | Brain Metastases | Brain LesionsUnited States
-
Hamad Medical CorporationUnknownEssential Thrombocythemia | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic StageQatar
-
Hamad Medical CorporationTerminatedPolycythemia Vera | Essential Thrombocythemia | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic StageQatar